參考文獻(xiàn)/References:
[1] 雷欣東,于慧,龍瓊,等.絕經(jīng)后骨質(zhì)疏松癥發(fā)病機(jī)制研究進(jìn)展[J].中國骨質(zhì)疏松雜志,2021,27(11):1681-1684.
[2] 中華醫(yī)學(xué)會骨質(zhì)疏松和骨礦鹽疾病分會.原發(fā)性骨質(zhì)疏松癥診療指南(2022)[J].中國全科醫(yī)學(xué),2023,26(14):1671-1691.
[3] SALARI N,GHASEMI H,MOHAMMADI L,et al.The glo-bal prevalence of osteoporosis in the world:a comprehensive systematic review and meta-analysis[J].J Orthop Surg Res,2021,16(1):609.
[4] 邱曉萍,劉鎧婕,林宇慧,等.骨質(zhì)疏松癥的流行病學(xué)、管理與防治研究進(jìn)展[J].山東醫(yī)藥,2023,63(21):107-111.
[5] 盛玲玲,李先娜,霍金海,等.骨質(zhì)疏松癥動物模型及評價方法研究進(jìn)展[J].黑龍江中醫(yī)藥,2018,47(6):111-113.
[6] 張奕奮,耿倚云,段莉,等.構(gòu)建骨質(zhì)疏松動物模型研究進(jìn)展[J].生物骨科材料與臨床研究,2021,18(2):62-66.
[7] 李彥冉,閆盼盼,苗艷艷,等.骨質(zhì)疏松動物模型構(gòu)建進(jìn)展與應(yīng)用特點分析[J].中國實驗動物學(xué)報,2023,31(7):928-934.
[8] LI B,WANG Y,GONG S,et al.Puerarin improves OVX-induced osteoporosis by regulating phospholipid metabolism and biosynthesis of unsaturated fatty acids based on serum metabolomics[J].Phytomedicine,2022,102:154198.
[9] SONG H,POLK J D,KERSH M E.Rat bone properties and their relationship to gait during growth[J].J Exp Biol,2019,222(Pt 18):jeb203554.
[10] 張洪,鮑波.淺談國內(nèi)BALB/c小鼠及KM小鼠的基本生物學(xué)特性[J].中國實用醫(yī)藥,2010,5(3):252-254.
[11] BATOON L,MILLARD S M,RAGGATT L J,et al.Osteal macrophages support osteoclast-mediated resorption and contribute to bone pathology in a postmenopausal osteoporosis mouse model[J].J Bone Miner Res,2021,36(11):2214-2228.
[12] WANG L,DING Y Y,WU Y Q,et al.Koumine ameliorates neuroinflammation by regulating microglia polarization via activation of Nrf2/HO-1 pathway[J].Biomed Pharmacother,2023,167:115608.
[13] YANG L,ZHANG B,LIU J,et al.Protective effect of acteo-side on ovariectomy-induced bone loss in mice[J]. Int J Mol Sci,2019,20(12):2974.
[14] 王起家,李可大,張江.骨質(zhì)疏松動物模型研究進(jìn)展[J].實用中醫(yī)內(nèi)科雜志,2023,37(9):134-138.
[15] KONG J Y,SU F Q,LIU Y,et al.The pharmacokinetics of buserelin after intramuscular administration in pigs and cows[J].BMC Vet Res,2022,18(1):136.
[16] 尹航,董博,康武林,等.補(bǔ)腎復(fù)方在絕經(jīng)后骨質(zhì)疏松癥動物模型中的研究進(jìn)展[J].中醫(yī)藥導(dǎo)報,2022,28(9):110-113.
[17] 周丹妮,衛(wèi)若楠,康夢嬌,等.圍絕經(jīng)期綜合征動物模型研究進(jìn)展[J].中國實驗方劑學(xué)雜志,2021,27(18):243-250.
[18] BRENT M B.Pharmaceutical treatment of bone loss:from animal models and drug development to future treatment strategies[J].Pharmacol Ther,2023,244:108383.
[19] THOMPSON D D,SIMMONS H A,PIRIE C M,et al.FDA guidelines and animal models for osteoporosis[J].Bone,1995,17(4 Suppl):125S-133S.
[20] BONJOUR J P,AMMANN P,RIZZOLI R.Importance of preclinical studies in the development of drugs for treatment of osteoporosis:a review related to the 1998 WHO guidelines[J].Osteoporos Int,1999,9(5):379-393.
[21] 馬艷芳,張鑫,李慧,等.骨質(zhì)疏松癥動物模型中大鼠卵巢切除手術(shù)要點及其術(shù)后護(hù)理[J].實驗動物科學(xué),2022,39(3):57-62.
[22] 李明,呂厚辰,尹鵬濱,等.兩種卵巢切除術(shù)式建立大鼠骨質(zhì)疏松模型的優(yōu)勢比較[J].解放軍醫(yī)學(xué)院學(xué)報,2015,36(4):383-387.
[23] KARAM N,LAVOIE J F,ST-JACQUES B,et al.Bone-specific overexpression of PITX1 induces senile osteoporosis in mice through deficient self-renewal of mesenchymal progenitors and Wnt pathway inhibition[J].Sci Rep,2019,9(1):3544.
[24] TANAKA T,TAKAHASHI A,KOBAYASHI Y,et al.Foxf2 represses bone formation via Wnt2b/β-catenin signaling[J].Exp Mol Med,2022,54(6):753-764.
[25] XU R,SHEN X,XIE H,et al.Identification of the canonical and noncanonical role of miR-143/145 in estrogen-deficient bone loss[J].Theranostics,2021,11(11):5491-5510.
[26] MELANIE V,ARKADIUSZ O,SABRINA S,et al.An antagonistic monoclonal anti-Plexin-B1 antibody exerts therapeutic effects in mouse models of postmenopausal osteoporosis and multiple sclerosis[J]. J Biol Chem,2022,298(9):102265.
[27] NI X,WU B,LI S,et al.Equol exerts a protective effect on postmenopausal osteoporosis by upregulating OPG/RANKL pathway[J].Phytomedicine,2023,108:154509.
[28] 付曉寧,胡朝暉.骨代謝生化指標(biāo)對于骨質(zhì)疏松癥診斷與治療的臨床意義[J].中國骨與關(guān)節(jié)損傷雜志,2018,33(9):1003-1005.
[29] 劉蔚楠,周曉霞,朱瑋,等.益腎健骨膏對去卵巢骨質(zhì)疏松大鼠骨代謝的影響[J].中國骨質(zhì)疏松雜志,2022,28(6):857-862.
[30] ZHANG J,ZHANG Q,LIU H,et al.Soy-whey dual-protein alleviates osteoporosis of ovariectomized rats via regulating bone fat metabolism through gut-liver-bone axis[J].Nutrition,2022,103/104:111723.
[31] LARRAÑAGA-VERA A, TOTI K S, FLATOW J S,et al.Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models[J]. Arthritis Res Ther,2022,24(1):265.
[32] 劉文靜,楊娟,張楚天,等.巴戟天抗去卵巢骨質(zhì)疏松大鼠的血清代謝組分析[J].中國藥理學(xué)通報,2022,38(3):446-453.
[33] 葉維建,李國山,黃建芳.甲狀旁腺激素對絕經(jīng)后骨質(zhì)疏松大鼠骨密度和骨生物力學(xué)的影響[J].中國老年學(xué)雜志,2022,42(8):1991-1994.
[34] ZHENG L,ZHUANG Z,LI Y,et al.Bone targeting antioxidative nano-iron oxide for treating postmenopausal osteoporosis[J].Bioact Mater,2022,14:250-261.
[35] 許勇,謝賢斐,顏威,等.木犀草素調(diào)控PI3K/AKT通路改善絕經(jīng)后骨質(zhì)疏松癥大鼠模型骨丟失的機(jī)制[J].熱帶醫(yī)學(xué)雜志,2022,22(5):639-643.
[36] 文枝,于慧,龍瓊,等.基于藥效成分比較研究山萸肉酒制前后分別配伍入六味地黃湯對絕經(jīng)后骨質(zhì)疏松癥模型大鼠的干預(yù)作用[J/OL].世界科學(xué)技術(shù)-中醫(yī)藥現(xiàn)代化,2023[2023-12-1]. https://link.cnki.net/urlid/11.5699.r.20231123.1644.004.
[37] ZHOU E,XIANG D,YU B,et al.Ovarian tissue transplantation ameliorates osteoporosis and dyslipidaemia in ovariectomised mice[J].J Ovarian Res,2022,15(1):139.
[38] ZHAO Y,XU Y,ZHENG H,et al.QingYan formula extracts protect against postmenopausal osteoporosis in ovariectomized rat model via active ER-dependent MEK/ERK and PI3K/Akt signal pathways[J].J Ethnopharmacol,2021,268:113644.
[39] TAO H,LI W,ZHANG W,et al.Urolithin A suppresses RANKL-induced osteoclastogenesis and postmenopausal osteoporosis by,suppresses inflammation and downstream NF-κB activated pyroptosis pathways[J].Pharmacol Res,2021,174:105967.
[40] 凌家艷,劉慶,馬威,等.補(bǔ)腎通絡(luò)方對去勢大鼠骨質(zhì)疏松癥模型子宮內(nèi)膜和骨量流失的影響[J].中醫(yī)藥導(dǎo)報,2022,28(6):20-23.
相似文獻(xiàn)/References:
[1]李林軍.應(yīng)用膨脹式椎弓根螺釘內(nèi)固定治療合并骨質(zhì)疏松的
胸腰椎退行性疾病[J].中醫(yī)正骨,2015,27(08):49.
[2]李學(xué)朋,朱立國.骨疏康膠囊對去卵巢大鼠骨小梁的影響[J].中醫(yī)正骨,2015,27(12):12.
LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康膠囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(12):12.
[3]陳冠軍,陳揚,莊汝杰.可灌注骨水泥椎弓根螺釘系統(tǒng)
在老年腰椎疾患手術(shù)中的應(yīng)用[J].中醫(yī)正骨,2015,27(02):40.
[4]王丹輝,賁越,韓梅.林蛙油治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2014,26(01):27.
Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(12):27.
[5]黃建華,黃建武,李慧輝,等.加味左歸丸對絕經(jīng)后骨質(zhì)疏松癥肝腎不足證
患者骨密度的影響[J].中醫(yī)正骨,2013,25(11):19.
Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(12):19.
[6]項旻,楊虹,林愛菊,等.絕經(jīng)后2型糖尿病患者骨質(zhì)疏松與血微量元素的關(guān)系研究[J].中醫(yī)正骨,2013,25(12):20.
Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(12):20.
[7]史曉林,李春雯,張志強(qiáng).弱陽離子磁珠分離技術(shù)和基質(zhì)輔助激光解吸電離飛行時間質(zhì)譜技術(shù)在原發(fā)性Ⅰ型骨質(zhì)疏松癥血清標(biāo)志蛋白篩選中的應(yīng)用[J].中醫(yī)正骨,2014,26(03):5.
Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(12):5.
[8]李明,徐明雄,馮左基,等.自擬壯骨方治療絕經(jīng)后骨質(zhì)疏松癥的療效及作用機(jī)制研究[J].中醫(yī)正骨,2014,26(09):21.
Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(12):21.
[9]陳俊杰,李晴晴,夏瑢.脂代謝及血清內(nèi)脂素水平與絕經(jīng)后骨質(zhì)疏松癥的
相關(guān)性研究[J].中醫(yī)正骨,2012,24(04):16.
CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(12):16.
[10]許超,肖魯偉,吳承亮.絕經(jīng)后女性骨質(zhì)疏松癥辨證分型與抑郁焦慮的關(guān)系研究[J].中醫(yī)正骨,2011,23(12):3.
XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(12):3.
[11]韓艷,溫利平,劉娜,等.補(bǔ)腎活血方對去卵巢大鼠骨代謝及骨密度的影響[J].中醫(yī)正骨,2015,27(12):7.
HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(補(bǔ)腎活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(12):7.
[12]歐國峰,劉鑫,董博,等.絕經(jīng)后骨質(zhì)疏松癥的免疫學(xué)研究進(jìn)展[J].中醫(yī)正骨,2016,28(08):70.
[13]施振宇,劉鐘,陳文亮,等.中醫(yī)綜合療法防治絕經(jīng)后骨量減少的多中心臨床研究[J].中醫(yī)正骨,2017,29(04):1.
SHI Zhenyu,LIU Zhong,CHEN Wenliang,et al.A multicenter clinical study of complex therapy of traditional Chinese medicine for prevention and treatment of postmenopausal osteopenia[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(12):1.
[14]梁文娜,李西海,李燦東.血清microRNA與絕經(jīng)后骨質(zhì)疏松癥腎虛證的關(guān)系[J].中醫(yī)正骨,2017,29(10):53.
[15]梁文娜,李西海,胡柳,等.二至丸抑制絕經(jīng)后骨質(zhì)疏松大鼠骨代謝紊亂的作用機(jī)制研究[J].中醫(yī)正骨,2017,29(11):1.
LIANG Wenna,LI Xihai,HU Liu,et al.Study on mechanism of action of Erzhi Wan(二至丸)in inhibiting bone metabolism disorder in rats with postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(12):1.
[16]劉晨,李興勇,姚興璋,等.絕經(jīng)后骨質(zhì)疏松癥的流行病學(xué)概況及發(fā)病機(jī)制研究進(jìn)展[J].中醫(yī)正骨,2018,30(03):52.
[17]楊依然,劉鐘,毛一凡,等.酪蛋白激酶-2相互作用蛋白1基于磷脂酰肌醇3-激酶/蛋白激酶B/哺乳動物雷帕霉素靶蛋白通路參與絕經(jīng)后骨質(zhì)疏松癥發(fā)生發(fā)展過程中細(xì)胞自噬的機(jī)制[J].中醫(yī)正骨,2018,30(04):59.
[18]曹俊青,鄭劍南,張麟.右歸丸聯(lián)合阿侖膦酸鈉口服治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證的臨床研究[J].中醫(yī)正骨,2018,30(05):20.
CAO Junqing,ZHENG Jiannan,ZHANG Lin.A clinical study of oral application of Yougui Wan(右歸丸)and alendronate sodium for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(12):20.
[19]李中萬,徐紹俊,楊廣鋼,等.健腎方聯(lián)合碳酸鈣D3咀嚼片(Ⅱ)
治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證[J].中醫(yī)正骨,2018,30(08):11.
LI Zhongwan,XU Shaojun,YANG Guanggang,et al.Oral application of Jianshen Fang(健腎方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(12):11.
[20]趙凡,劉全,吳連國.口服強(qiáng)骨飲聯(lián)合碳酸鈣D3片治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2019,31(04):26.
ZHAO Fan,LIU Quan,WU Lianguo.Oral applications of Qianggu Yin(強(qiáng)骨飲)and calcium carbonate and Vitamin D3 tablets for treatment of postmenopausal osteoporosis:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(12):26.